Pierce Christopher's Form 4 filing
Prelude Therapeutics Inc (PRLD) · filed Sep 7, 2021
- Accession no.
- 0001209191-21-055072
- Filed
- Sep 7, 2021
- Trade date
- Sep 2, 2021
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $708.5K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pierce ChristopherCIK 0001824631 | Officer (EVP and Chief of Business Oper) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2021 | Common Stock | MOption exerciseAcquired | +17,000 | $12.85 | +$218,450 | 20,750 | Direct | |
| Sep 2, 2021 | Common Stock | SSaleDisposed | −3,343 | $40.29 | −$134,689.47 | 17,407 | Direct | |
| Sep 2, 2021 | Common Stock | SSaleDisposed | −6,727 | $41.52 | −$279,305.04 | 10,680 | Direct | |
| Sep 2, 2021 | Common Stock | SSaleDisposed | −6,930 | $42.50 | −$294,525 | 3,750 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2021 | Common Stock | MOption exerciseDisposed | −17,000 | $0.00 | $0 | 207,796 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.